Moderna (NASDAQ:MRNA) Stock Price Up 3.9% – Should You Buy?

Moderna, Inc. (NASDAQ:MRNA) shares rose 3.9% during trading on Tuesday . The stock traded as high as $57.42 and last traded at $56.91. Approximately 884,791 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 4,323,301 shares. The stock had previously closed at $54.80.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, September 13th. TD Cowen decreased their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Jefferies Financial Group dropped their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. JPMorgan Chase & Co. downgraded Moderna from a “neutral” rating to an “underweight” rating and cut their target price for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. Finally, UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $94.65.

Moderna Stock Up 0.5 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The business has a 50 day simple moving average of $66.97 and a 200 day simple moving average of $102.38. The stock has a market cap of $21.11 billion, a PE ratio of -3.50 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.62) earnings per share. On average, equities research analysts forecast that Moderna, Inc. will post -9.88 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,184 shares of company stock worth $2,037,931 in the last quarter. 15.70% of the stock is currently owned by company insiders.

Institutional Trading of Moderna

Hedge funds have recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Moderna by 42.9% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares during the period. Lake Street Private Wealth LLC bought a new position in shares of Moderna during the 1st quarter worth approximately $239,000. Norden Group LLC acquired a new stake in shares of Moderna during the 1st quarter worth about $1,337,000. Westside Investment Management Inc. bought a new position in shares of Moderna in the first quarter valued at approximately $32,000. Finally, Abundance Wealth Counselors boosted its holdings in shares of Moderna by 20.7% in the 1st quarter. Abundance Wealth Counselors now owns 4,863 shares of the company’s stock worth $518,000 after acquiring an additional 835 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.